Triple meeting 2023 – Revolution’s KRAS revolution promise draws fans
Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.
Triple meeting 2023 preview – firsts for Amgen and Novartis
But Repare and Black Diamond still have rebuilding to do.
ESMO 2023 preview – Pluvicto splashes down among the late-breakers
Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.
Mirati secures an independent future
Mirati raises $300m as its chief exec departs. What’s not to like?
Not the sort of Revolution that EQRX had dreamt of
EQRX had once hoped to disrupt cosy US cancer drug pricing arrangements, but when that model failed the group found that cash was its best asset.
